QUOTED. Jan. 8, 2018. Susan Stimson.
Executive SummaryCheck out what Intersect ENT's Susan Stimson had to say about efforts the manufacturer is making to evolve from a medical device company to a combination products company.
"We are really focused on this new business model, of not just selling combination products, but being a combination company selling both drugs and devices. Larger companies might have divisions that focus on either drugs or devices, but at Intersect ENT, given that this will be used by the same customers on the same patients, we decided it was important to lead this new effort to become a pharmaceutical – as well as a medical device – company and utilize innovative ideas throughout to make sure that feels seamless to our customers." –Susan Stimson, general manager, Intersect ENT Inc.
Click here for a free trial of Medtech Insight